Glenmark received USFDA approval for headache drug
The approval will allow the company to sell generic versions of AstraZeneca's Zomig and ZomigZMT tablets, a migraine drug in the US market.
New Delhi, May 16, 2013: Glenmark Pharmaceuticals has received approval from the US health regulator to sell generic versions of AstraZeneca's Zomig and ZomigZMT tablets, a migraine drug in the US market.
Glenmark Generics Inc, a subsidiary of Glenmark has received approval from US Food and Drug Administration (USFDA) for Zolmitriptan Tablets and Zolmitriptan Orally Disintegrating tablets, Glenmark said in a statement.
The company also said that it plans to commence the distribution of the product immediately. It may be noted here that Zolmitriptan Tablets and Zolmitriptan ODT are indicated for the acute treatment of migraine headaches in adults.
For the 12-month period ended December 2012, the products stood at annual sales of US$ 176 million, as per IMS Health data.